Cargando…
Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen
BACKGROUND: Rifabutin‐based regimens are used as rescue therapy for refractory Helicobacter pylori infection; however, the duration for which treatment is required and side effects are concerning. This study assessed the efficacy and safety of 7‐day rifabutin, amoxicillin, and vonoprazan triple ther...
Autores principales: | Inokuchi, Kazumi, Mori, Hideki, Matsuzaki, Juntaro, Hirata, Kenro, Harada, Yosuke, Saito, Yoshimasa, Suzuki, Hidekazu, Kanai, Takanori, Masaoka, Tatsuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539484/ https://www.ncbi.nlm.nih.gov/pubmed/35644041 http://dx.doi.org/10.1111/hel.12900 |
Ejemplares similares
-
Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy
por: Hirata, Kenro, et al.
Publicado: (2013) -
Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
por: Mori, Hideki, et al.
Publicado: (2022) -
Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia
por: Matsuzaki, Juntaro, et al.
Publicado: (2019) -
Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021) -
Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
por: Borraccino, Antonia Valeria, et al.
Publicado: (2022)